MUNICH, Germany and TEL AVIV, Israel, June 01, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased to announce a pioneering collaboration with the German company, Particle Metrix, a leading provider of particle analysis devices. In connection with the collaboration, a highly-advanced Nanoparticle Tracking Analysis instrument ("NTA") has been recently placed. At NurExone’s laboratory, which is an important milestone in the expansion of NurExone’s production and analytic processes.
The newly acquired NTA, which is the first of its kind in Israel, is equipped with state-of-the-art capabilities including nanoparticle tracking analysis and advanced colocalization technology. The new system is a ZetaView TWIN Laser System PMX-230 using wavelengths of 520 and 640 nanometers for size, concentration, fluorescence, colocalization and Zeta Potential analysis. As part of the collaboration, the two companies will share analytical data between them in order to improve the colocalization performance of the device at these 2 wavelengths.
NurExone plans to leverage the capabilities of the advanced NTA to validate its methodology for analysis of loaded exosomes, a vital part of the development process of its ExoPTEN drug, targeted at the $2.9 billion global market for patients with acute spinal cord injury. In line with its business strategy of monetizing its knowledge and capabilities, NurExone will also be able to offer the NTA services to other companies developing exosome-based therapies for other indications.
"We firmly believe that exosome-based therapies have the potential to be the next frontier in drug delivery systems and are thrilled to collaborate with NurExone and deliver in Israel for the first time a state-of-the-art ZetaView® TWIN Laser System," noted Dr. Clemens Helmbrecht, Managing Director of Particle Metrix.
"We are delighted to integrate this one-of-its-kind system into our analytics procedure and quality control, further advancing our capabilities for analyzing exosomes loaded with therapeutic cargo," stated Dr. Lior Shaltiel, Chief Executive Officer of NurExone. "We anticipate a transformative impact on our quality process in order to develop the highest quality of life-changing therapies for central nervous system patients worldwide."
About Particle Metrix
Particle Metrix is an innovative German technology company at the forefront of nanoparticle analysis solutions. The state-of-the-art systems provide accurate measurements of size, concentration, zeta potential, fluorescence and colocalization of nanoparticles empowering researchers and engineers to optimize processes, enhance product quality, and drive scientific advancements. With a commitment to excellence and a customer-centric approach, Particle Metrix revolutionizes particle analysis, delivering reliable results and actionable insights to foster success in diverse scientific and industrial applications.
For further information, please visit https://particle-metrix.com.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSX Venture Exchange-listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.
ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the Company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.
For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For further information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Inbar Paz-Benayoun
Adv. Head of Communications and Investor Relations
Phone: +972-52-3966695
Email: info@nurexone.com
Investor Relations (Canada) Phone: +1 905-347-5569
Email: IR@nurexone.com
FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" that reflect the Company's current expectations and projections about its future development and production process. When used in this press release, forward-looking statements can be identified by the use of words such as "may," or by such words as "will," "intend," "believe," "estimate," "consider," "expect," "anticipate," and "objective" and similar expressions or variations of such words. Forward-looking statements are, by their nature, not guarantees of the Company's future operational or financial performance and are subject to risks and uncertainties and other factors that could cause the Company's actual results, performance, prospects, or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. No representation or warranty is intended with respect to anticipated future results, or that estimates, or projections will be sustained.
Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions, and expected future developments, as well as the factors we believe are appropriate. Forward- looking statements in this press release include, but are not limited to, statements relating to: the uses and implementation of the NTA; our future plans and intellectual property; our scientific and development activities; future scientific activities and the treatment of certain conditions; the therapeutic benefits, effectiveness, and safety of our product candidates; and the estimated growth of the market for acute spinal cord injuries.
In developing the forward-looking statements in this press release, we have applied several material assumptions, our ability to retain key personnel, our ability to continue investing in research and development, our ability to secure available funding and to continue as a going concern; the general business and economic conditions of the industries and countries in which we operate; and our ability to execute on our business strategy.
Many risks, uncertainties, and other factors could cause the actual results of the Company to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the following: those risk factors identified under the heading "Risk Factors" on pages 29 to 36 of the Company's Annual Information Form dated March 30, 2023, a copy of which is available under the Company's SEDAR profile at www.sedar.com; risks related to the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for our products; rapid technological change; dependence on key personnel; protection of our intellectual property; dependence on our strategic partners; overall economic conditions; competitive pressures; network restrictions; and other similar factors that may cause the actual results, performance or achievements to differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the press release or as of the date otherwise specifically indicated herein. Due to risks and uncertainties, events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required pursuant to applicable securities law. All forward-looking statements contained in the press release are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
